Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.195-197
V. Coman, M. Vlassa, M. Filip, S. Beldean-Galea, T. Dicu, R. Coman
{"title":"Impact of one High Dose of Ceftazidime Administrated before Minimally Invasive Multimodal Endoscopic Prostate Surgery","authors":"V. Coman, M. Vlassa, M. Filip, S. Beldean-Galea, T. Dicu, R. Coman","doi":"10.33892/aph.2021.91.195-197","DOIUrl":"https://doi.org/10.33892/aph.2021.91.195-197","url":null,"abstract":"","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83976392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.222-223
V. I. Gegechkori, O. V. Saltykova, G. M. Rodionova
{"title":"Determination of Psychotropic Drugs by Thin-Layer Chromatography","authors":"V. I. Gegechkori, O. V. Saltykova, G. M. Rodionova","doi":"10.33892/aph.2021.91.222-223","DOIUrl":"https://doi.org/10.33892/aph.2021.91.222-223","url":null,"abstract":"","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88127033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.251-252
M. Király, B. Dalmadi Kiss, P. Horváth, L. Drahos, A. Mirzahosseini, G. Pálfy, I. Antal, K. Ludányi
{"title":"Investigating the Influence of Heat Stress to the Activity And Structural Changes of Lactase Enzyme","authors":"M. Király, B. Dalmadi Kiss, P. Horváth, L. Drahos, A. Mirzahosseini, G. Pálfy, I. Antal, K. Ludányi","doi":"10.33892/aph.2021.91.251-252","DOIUrl":"https://doi.org/10.33892/aph.2021.91.251-252","url":null,"abstract":"","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"97 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74862595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.216-217
László Forgách, N. Hegedűs, I. Horváth, K. Szigeti, D. Máthé
{"title":"Novel fluorescent Labelled, Pegylated Prussian Blue Nanoparticles for in vivo Optical Imaging","authors":"László Forgách, N. Hegedűs, I. Horváth, K. Szigeti, D. Máthé","doi":"10.33892/aph.2021.91.216-217","DOIUrl":"https://doi.org/10.33892/aph.2021.91.216-217","url":null,"abstract":"","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77926553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.198-199
Mohammed Séghir Daas, M. Faci, I. Nicoletti, M. Douzane, D. Corradini
A variety of plant secondary metabolites have a remarkable position as bioactive components in medicinal plants and have evidenced to exhibit numerous biological activities and several health benefits against chronic and degenerative human diseases. Moreover, secondary metabolites occurring in edible plants form an integral part of human diet, contributing to the sensory properties of plant-based aliments and to their beneficial effects on human health. Numerous are the instrumental analytical separation techniques that are employed to identify and quantify the bioactive compounds occurring in medicinal plants and plant-derived food products. Among them, high performance liquid chromatography, mostly in reversed phase separation mode (RP-HPLC) and generally coupled to mass spectrometry (MS), is the technique of choice for the identification and quantification of plant secondary metabolites. The optimization of HPLC methods is generally carried out by conventional trial-and-error approaches, requiring the screening of a variety of experimental conditions, which include column temperature, pH, composition of the mobile phases, as well as shape and duration of the gradient elution program (1). This communication describes the development of computer-assisted RP-HPLC methods for the separation, identification and quantification of phenolic compounds, which are a large class of plant secondary metabolites comprising a great number of heterogeneous structures that range from simple molecules to highly polymerized compounds.The study has been conducted by a Design of Experiments (DoE) approach that allow the simultaneous optimization of gradient time (tG), column temperature (T) and binary eluent composition on the basis of retention times and peak areas of the analytes of interest, obtained in twelve different experiments. These experiments consist in the linear gradient separations of the investigated compounds performed at two different gradient times and column temperatures, using either the aqueous component of the mobile phase at three different pH values or a combination of two organic solvents at three different volume ratios as the gradient former.The RP-HPLC methods developed by the computer-assisted approach described in this paper were used for the separation and quantification of phenolic compounds occurring in fruits of Olea europaea, extra virgin olive oil (EVOO) and olive mill waste water (OMWW). .
{"title":"Computer-Assisted Approach for the Development of RP-HPLC Methods for the Separation and Quantification of Bioactive Plant Secondary Metabolites","authors":"Mohammed Séghir Daas, M. Faci, I. Nicoletti, M. Douzane, D. Corradini","doi":"10.33892/aph.2021.91.198-199","DOIUrl":"https://doi.org/10.33892/aph.2021.91.198-199","url":null,"abstract":"A variety of plant secondary metabolites have a remarkable position as bioactive components in medicinal plants and have evidenced to exhibit numerous biological activities and several health benefits against chronic and degenerative human diseases. Moreover, secondary metabolites occurring in edible plants form an integral part of human diet, contributing to the sensory properties of plant-based aliments and to their beneficial effects on human health. Numerous are the instrumental analytical separation techniques that are employed to identify and quantify the bioactive compounds occurring in medicinal plants and plant-derived food products. Among them, high performance liquid chromatography, mostly in reversed phase separation mode (RP-HPLC) and generally coupled to mass spectrometry (MS), is the technique of choice for the identification and quantification of plant secondary metabolites. The optimization of HPLC methods is generally carried out by conventional trial-and-error approaches, requiring the screening of a variety of experimental conditions, which include column temperature, pH, composition of the mobile phases, as well as shape and duration of the gradient elution program (1). This communication describes the development of computer-assisted RP-HPLC methods for the separation, identification and quantification of phenolic compounds, which are a large class of plant secondary metabolites comprising a great number of heterogeneous structures that range from simple molecules to highly polymerized compounds.The study has been conducted by a Design of Experiments (DoE) approach that allow the simultaneous optimization of gradient time (tG), column temperature (T) and binary eluent composition on the basis of retention times and peak areas of the analytes of interest, obtained in twelve different experiments. These experiments consist in the linear gradient separations of the investigated compounds performed at two different gradient times and column temperatures, using either the aqueous component of the mobile phase at three different pH values or a combination of two organic solvents at three different volume ratios as the gradient former.The RP-HPLC methods developed by the computer-assisted approach described in this paper were used for the separation and quantification of phenolic compounds occurring in fruits of Olea europaea, extra virgin olive oil (EVOO) and olive mill waste water (OMWW). .","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87763089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.326-327
T. Varga, I. Klebovich, M. Kraszni
{"title":"Comparative Analysis of Silybum Marianum Fruit Extracts and Thyme Oil Samples Using NMR-based Multivariate Statistical Methods","authors":"T. Varga, I. Klebovich, M. Kraszni","doi":"10.33892/aph.2021.91.326-327","DOIUrl":"https://doi.org/10.33892/aph.2021.91.326-327","url":null,"abstract":"","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"149 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90595482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.324-325
T. Upmanis, H. Kažoka
{"title":"Application of Commercially Available Crown Ether Chiral Stationary Phases for Separation of Tetrapeptide Stereoisomers","authors":"T. Upmanis, H. Kažoka","doi":"10.33892/aph.2021.91.324-325","DOIUrl":"https://doi.org/10.33892/aph.2021.91.324-325","url":null,"abstract":"","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88643410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.337-339
Lamija Hindija, J. Hadžiabdić, O. Rahić, Amina Tucak-Smajić, M. Sirbubalo, I. Klebovich, E. Vranić
Dimenhydrinate (DMH) is used for the prevention and treatment of nausea, vomiting, dizziness and vertigo associated with motion sickness in a dose of 50 mg 1. It’s made of two drugs in a form of salt, diphenhydramine and 8-chlorotheophylline which synergically decrease motion caused neural excitation 2. DMH is classified as a slightly soluble drug and it belongs to class II of BCS classification as a drug with low solubility and high permeability 3. Cyclodextrins (CDs) are cyclic oligosaccharides formed by α-1,4-linked glucose units with a hydrophilic outer surface and a lipophilic central cavity. Formation of inclusion complex by incorporating a drug in the central CD cavity provides improvement of physicochemical properties without molecular modifications. Solubility and dissolution rate of poorly water-soluble drugs can be increased 4. Aqueous solubility of natural CDs is limited due to their tendency to form H-bonded associations. However, due to multiple reactive hydroxyl groups, their functionality can be greatly increased by chemical modification 5. CDs’ substituted derivates can overcome poor solubility issues and enhance bioavailability. Hydroxypropylβ-CD (HP-β-CD) has good inclusion ability, high water solubility and it’s safe for intravenous and oral administration 6. Stability constant (Ks) and complexation efficacy (CE) are important for assessing the binding characteristics of the drug and CD. They can be determined by the phase solubility studies where the change of the drug solubility is corresponding to the concentration of CD 7. Linear (AL) type of the curve implies that one molecule of the drug forms inclusion complex with one molecule of the CD. Apparent stability constant K1:1 can be calculated from the following equation:
苯海明(DMH)用于预防和治疗与晕车相关的恶心、呕吐、头晕和眩晕,剂量为50毫克1。它是由两种盐形式的药物,苯海拉明和8-氯茶碱组成的,它们协同减少运动引起的神经兴奋。DMH属于微溶性药物,属于BCS分类II类,是一种低溶解度、高通透性的药物3。环糊精(CDs)是由α-1,4连接的葡萄糖单元形成的环状低聚糖,具有亲水的外表面和亲脂的中心腔。通过在中央CD腔中加入药物形成包合物,可以在没有分子修饰的情况下改善物理化学性质。可提高水溶性差药物的溶解度和溶出率。天然CDs的水溶性受到限制,因为它们倾向于形成氢键结合。然而,由于有多个活性羟基,它们的功能可以通过化学修饰大大提高5。CDs取代衍生物可以克服溶解度差的问题,提高生物利用度。羟丙基β- cd (HP-β-CD)包合能力好,水溶性高,静脉和口服给药安全。稳定性常数(Ks)和络合效能(CE)是评估药物与cd7结合特性的重要指标。它们可以通过相溶解度研究来确定,其中药物溶解度的变化对应于cd7的浓度。线性(AL)型曲线表明药物的一个分子与CD的一个分子形成包合物。表观稳定常数K1:1可由下式计算:
{"title":"Effect of Molar Mass of Hydroxypropyl β-cyclodextrin on the Aqueous Solubility of Dimenhydrinate","authors":"Lamija Hindija, J. Hadžiabdić, O. Rahić, Amina Tucak-Smajić, M. Sirbubalo, I. Klebovich, E. Vranić","doi":"10.33892/aph.2021.91.337-339","DOIUrl":"https://doi.org/10.33892/aph.2021.91.337-339","url":null,"abstract":"Dimenhydrinate (DMH) is used for the prevention and treatment of nausea, vomiting, dizziness and vertigo associated with motion sickness in a dose of 50 mg 1. It’s made of two drugs in a form of salt, diphenhydramine and 8-chlorotheophylline which synergically decrease motion caused neural excitation 2. DMH is classified as a slightly soluble drug and it belongs to class II of BCS classification as a drug with low solubility and high permeability 3. Cyclodextrins (CDs) are cyclic oligosaccharides formed by α-1,4-linked glucose units with a hydrophilic outer surface and a lipophilic central cavity. Formation of inclusion complex by incorporating a drug in the central CD cavity provides improvement of physicochemical properties without molecular modifications. Solubility and dissolution rate of poorly water-soluble drugs can be increased 4. Aqueous solubility of natural CDs is limited due to their tendency to form H-bonded associations. However, due to multiple reactive hydroxyl groups, their functionality can be greatly increased by chemical modification 5. CDs’ substituted derivates can overcome poor solubility issues and enhance bioavailability. Hydroxypropylβ-CD (HP-β-CD) has good inclusion ability, high water solubility and it’s safe for intravenous and oral administration 6. Stability constant (Ks) and complexation efficacy (CE) are important for assessing the binding characteristics of the drug and CD. They can be determined by the phase solubility studies where the change of the drug solubility is corresponding to the concentration of CD 7. Linear (AL) type of the curve implies that one molecule of the drug forms inclusion complex with one molecule of the CD. Apparent stability constant K1:1 can be calculated from the following equation:","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90816258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-15DOI: 10.33892/aph.2021.91.148-149
P. Macheras
From the early days of Pharmacokinetics (1) drug absorption was modeled as a first-order process implying an infinite time for drug absorption. According to the current scientific knowledge and common wisdom, drugs are absorbed passively in finite time. The concept of “finite time” of absorption has been used in various Physiologically Based Pharmacokinetic (PBPK) models. However, the formal development of Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models was published recently (2-5). The PBFTPK models were built on two principles: i) drugs are absorbed passively for a finite period of time, τ and ii) time absorption constrains linked with the gastrointestinal transit times of drug in the stomach, the small intestines and the colon were applied (2-5). Zeroor first-order input is used for the (PBFTPK)0 and (PBFTPK)1 models, respectively.
{"title":"Drugs are Absorbed in Finite Time: A New Era in Biopharmaceutics and Pharmacokinetics","authors":"P. Macheras","doi":"10.33892/aph.2021.91.148-149","DOIUrl":"https://doi.org/10.33892/aph.2021.91.148-149","url":null,"abstract":"From the early days of Pharmacokinetics (1) drug absorption was modeled as a first-order process implying an infinite time for drug absorption. According to the current scientific knowledge and common wisdom, drugs are absorbed passively in finite time. The concept of “finite time” of absorption has been used in various Physiologically Based Pharmacokinetic (PBPK) models. However, the formal development of Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models was published recently (2-5). The PBFTPK models were built on two principles: i) drugs are absorbed passively for a finite period of time, τ and ii) time absorption constrains linked with the gastrointestinal transit times of drug in the stomach, the small intestines and the colon were applied (2-5). Zeroor first-order input is used for the (PBFTPK)0 and (PBFTPK)1 models, respectively.","PeriodicalId":6941,"journal":{"name":"Acta pharmaceutica Hungarica","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89221410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}